Capstone Receives Multiple Orders for Offshore Platforms from New Alaska Distributor Chenega Energy
Capstone Turbine Corporation (www.capstoneturbine.com) (CPST), the world's leading clean technology manufacturer of microturbine energy systems, today announced that it received multiple orders for oil and gas offshore platforms from its new Alaskan distributor Chenega Energy LLC. The orders are for a single C1000 and multiple C200s for use on offshore platforms in Alaska's Cook Inlet.
Chenega Energy secured the orders from Hilcorp Alaska LLC, which purchased 10 oilrigs in Alaska's Cook Inlet from Chevron and Marathon Oil in 2012 and 2013. Since January 2012, oil production on the platforms has increased by 36 percent to approximately 9,700 barrels per day. Despite this increase, cost of oil production remains high and Hilcorp plans to invest over $500 million to further develop this project and make structural changes to help drive down costs.
The Medicines Company Acquires Rempex Pharmaceuticals
Novel Portfolio of Gram-Negative Antibiotics in Development Added to The Medicines Company's Infectious Disease Hospital Care Franchise The Medicines Company (NASDAQ: MDCO) today announced that it has acquired Rempex Pharmaceuticals, Inc., a company with multiple potential new therapies focused on multi-drug resistant gram-negative bacteria.
Clive Meanwell, MD, PhD, Chairman and Chief Executive Officer of The Medicines Company, said, "Acute and intensive care hospitals around the world face rapid and increasing antibacterial resistance, especially to gram-negative pathogens. The assets of Rempex, particularly Carbavance™, will allow us to intensify our efforts to save lives, alleviate suffering and contribute to the economics of healthcare by serving leading hospitals."
ARCA biopharma Announces US FDA Acceptance of Gencaro IND Application for the Treatment of Atrial Fibrillation
Phase 2B/3 GENETIC-AF Trial on Track to Begin Patient Enrollment in Q1 2014 Gencaro Potentially the First Genetically-Targeted Cardiovascular Treatment
ARCA biopharma, Inc. (ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the Company’s GencaroTM Investigational New Drug (IND) application for atrial fibrillation (AF) has been accepted by the U.S. Food and Drug Administration (FDA) and is now active.
Oculus Innovative Sciences Receives FDA Clearance for Microcyn(R) Scar Management HydroGel
Oculus U.S Dermatology Partner, Quinnova Pharmaceuticals, Targeting U.S. Launch in Q2 2014
U.S. Double-Blind, Randomized Study for Scar Management Establishes Strong Foundation for International Approval
Oculus Innovative Sciences, Inc. (OCLS), a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 27 countries, today announced that it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company's new Microcyn(R) Scar Management HydroGel.
Conatus Pharmaceuticals Receives U.S. Orphan Drug Designation for Emricasan for Treatment of Liver Transplant Recipients With Reestablished Fibrosis
Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Conatus' drug candidate emricasan for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end-stage liver disease. The FDA's Orphan Drug Designation program is intended to encourage the development of drugs and biologics that may provide benefit to patients suffering from rare diseases or conditions.
OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple Anti-Cancer Stem Cell Therapeutics to Offer Potential Benefits to Cancer Patients
Celgene Invests in OncoMed's Demcizumab and up to Five Additional Preclinical Biologics Programs; OncoMed Leads Early Clinical Trials and Retains Co-Development, Co-Commercialization and Profit-Sharing Rights
OncoMed to Receive $177.25 Million Upfront, Including a $22.25 Million Equity Investment
OncoMed Pharmaceuticals, Inc. (OMED) and Celgene Corporation (CELG) today announced an agreement to jointly develop and commercialize up to six anti-cancer stem cell (CSC) product candidates from OncoMed's biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4).
ICU Medical Receives Premier Inc. Contract for the New Diana™ Hazardous Drug Compounding System with Barcode Scanning
New Six-Year Agreement Marks the First GPO Contract for ICU Medical's Breakthrough Automated Sterile Compounding System for the Accurate, Safe, and Efficient Preparation of Hazardous Drugs, Set to Debut at ASHP Midyear in Orlando, December 8-12
ICU Medical Inc. (ICUI) today announced it has been awarded a six-year group purchasing contract from Premier Inc. for the DianaTM hazardous drug compounding system, the world's first user-controlled, automated sterile compounding system for the accurate, safe, and efficient preparation of hazardous drugs. Effective in 2014, this is the first time the Diana system, introduced in the United States in 2012, has been on contract with a group purchasing organization. A new version of the Diana system that incorporates a barcode scanning system will be debuted at the American Society of Hospital Pharmacists (ASHP) midyear clinical meeting in Orlando, FL, December 8-12, 2013.
Digital Ally Receives Initial DVM-250 Order From Kansas City Transportation Group
Company Targets 5,000+ Vehicles Operated by Affiliates of Veolia Transportation
Digital Ally, Inc. (NASDAQ: DGLY), which develops, manufactures and markets advanced video surveillance products for law enforcement, homeland security and commercial applications, today announced that it has received an initial order for 100 DVM-250 Video Event Recorders from Kansas City Transportation Group ("KCTG"). Operating under the names "Yellow Cab", "10/10 Taxi", and "Super Shuttle", KCTG manages a fleet of over 400 transportation vehicles in the Kansas City metropolitan area.
B.O.S. Announces Financial Results for Third Quarter of 2013
Net Profit of $219,000 and NON GAAP Net Profit of $415,000
B.O.S. Better Online Solutions Ltd. (the "Company", "BOS") (BOSC), a leading Israeli provider of RFID and supply chain solutions to global enterprises, today reported its financial results for the three months ended September 30, 2013.
Highlights - on a GAAP basis:Revenues for the third quarter of 2013 grew by 16% as compared to the comparable quarter last year. Revenues for the first nine months of 2013 grew by 3%, as compared to the comparable period last year.
Intuit Standardizes on Splunk Software
Leader in Business and Financial Management Solutions Significantly Expands Splunk Software to Drive Operational Intelligence Across Organization
Splunk Inc. (SPLK), provider of the leading software platform for real-time operational intelligence, today announced that Intuit has selected Splunk Enterprise 6 as an enterprise-wide platform for operational intelligence. Intuit recently inked an Enterprise Adoption Agreement that vastly expands its use of Splunk Enterprise 6, and includes Hunk™: Splunk Analytics for Hadoop, the Splunk App for Enterprise Security, the Splunk App for VMware and the Splunk App for PCI Compliance. Intuit has been a Splunk customer since 2008, using Splunk products to collect, monitor, analyze and visualize the machine data generated by its leading business and financial management solutions including QuickBooks®, Quicken® and TurboTax®, among others.
ARIAD Announces Positive Opinion by the European Medicines Agency on the Continued Availability of Iclusig in Patients with Leukaemias
Recommendations made to minimize risk of occlusive vascular events
ARIAD Pharmaceuticals, Inc. (ARIA) today announced adoption of a positive opinion by the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) on the continued availability of Iclusig® (ponatinib) in the EU for use in patients in its authorized indications. Following its review of updated clinical-trial data on Iclusig, the CHMP made a series of recommendations on measures to help minimize the risk of occlusive vascular events in patients taking Iclusig. The authorized indications of Iclusig, as approved in July 2013, are as follows:
Aetrium Reports Orders for Multiple Units of VMAX IC Handlers
Aetrium Incorporated (ATRM) announced today recent bookings of multiple units of its VMAX IC test handlers. Daniel Koch, the recently appointed CEO of Aetrium, Incorporated today said, "We are all very pleased with the recent orders for our newest product offering, the VMAX IC test handler. It is especially pleasing to see both new customers and long term customers in our current backlog. All of these new orders are being driven by increased capacity needs and they are quite diverse in their end applications. The semiconductor industry continues to show signs of slow and deliberate recovery."
Ceragon Networks Ltd. Prices Underwritten Public Offering of Ordinary Shares
Ceragon Networks Ltd. (CRNT), today announced the pricing of an underwritten public offering of 14,000,000 of its ordinary shares at a price of $2.40 per share. The company has also granted to the underwriters a 30-day option to acquire an additional 1,600,000 shares to cover overallotments in connection with the offering. After the underwriting discount and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $31.4 million, assuming no exercise of the overallotment option. The offering is expected to close on November 26, 2013, subject to customary closing conditions.
Needham & Company is acting as lead book-running manager of the offering. Oppenheimer & Co. is acting as co-book runner.
Cardiovascular Systems Prices Public Offering of Common Stock
Cardiovascular Systems, Inc. (CSI) (CSII), a medical device company focused on developing and commercializing innovative interventional treatment systems for vascular disease, today announced the pricing of an underwritten public offering of 2,608,696 shares of its common stock, at a price to the public of $30.00 per share. The net proceeds to CSI from the sale of the shares, after deducting underwriting discounts and commissions and estimated expenses, are expected to be approximately $73.4 million. All of the shares in the offering are to be sold by CSI. The offering is expected to close on or about November 26, 2013.
In connection with the offering, CSI has also granted the underwriters a 30-day option to purchase up to an additional 391,304 shares.
Green Mountain Coffee Roasters Reports Full Fiscal Year and Fourth Quarter Fiscal 2013 Results
Green Mountain Coffee Roasters, Inc., (GMCR) (NASDAQ:GMCR - News), a leader in specialty coffee and coffee makers with its innovative Keurig® brewing technology, today announced its results for the 13 weeks and 52 weeks ended September 28, 2013.
“We had a strong end to an excellent year, driven by continued consumer passion for the Keurig brewing system,” said Brian P. Kelley, GMCR’s President and CEO. “Our 16% annual revenue growth and 22% revenue growth for the fourth quarter were driven by robust brewer sales and continued portion pack sales momentum.
CombiMatrix Announces Contract With America's Choice Provider Network(R)
Provides Access to Company's Suite of Molecular Tests to Additional 14 Million Members Nationally
CombiMatrix Corporation (CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that it has entered into a contractual agreement with America's Choice Provider Network(R) (ACPN(R)) for coverage of its diagnostic laboratory services.
The agreement with ACPN, a San Diego-based national healthcare savings provider network, provides access to CombiMatrix's suite of molecular diagnostic solutions and comprehensive clinical support—specializing in prenatal, miscarriage and pediatric healthcare—to more than 14 million members.
Unilife Signs Long-Term Supply Agreement with Hikma to Enhance Delivery of Generic Injectables
Unilife to receive $40MM in upfront and milestone payments 15-year supply agreement to launch initial 20 generic injectable drugs in syringes from Unifill platform Unilife to begin commercial supply in FY 2014, annual minimum unit volume to exceed 175MM
Unilife Corporation ("Unilife") (NASDAQ: UNIS, ASX: UNS) today announced the signing of a long-term commercial supply contract with Hikma Pharmaceuticals PLC ("Hikma") (HIK.L) for the use of Unifill® prefilled syringes with a range of generic injectable drugs.
SGOCO Group to Announce Financial Results for 2013 Third Quarter on November 20, 2013
SGOCO Group, Ltd. (SGOC), ("SGOCO" or the "Company"), a company focused on product design, distribution, and brand development in flat-panel display market, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2013 on Wednesday, November 20, 2013 after the U.S. market closes. The earnings press release will be available at http://www.sgocogroup.com
Following the earnings announcement, SGOCO's senior management will host a conference call on Thursday, November 21, 2013 at 8 a.m. (Eastern) / 5 a.m. (Pacific) / 9 p.m. (Beijing / Hong Kong) to discuss quarterly results and operational updates.
Horizon Pharma Announces Agreement to Acquire U.S. Rights to VIMOVO(R) and Provides 2014 Guidance
Horizon to Host Conference Call / Webcast Today at 8:00 a.m. EST
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that it has entered into an agreement to acquire from AstraZeneca AB the U.S. rights to VIMOVO® (naproxen/esomeprazole magnesium) delayed-release tablets, further expanding Horizon's focus on key primary care physician targets in the U.S. VIMOVO is approved in the U.S. to relieve the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of stomach (gastric) ulcers in patients at risk of developing stomach ulcers from treatment with NSAIDs. AstraZeneca will retain ex-U.S. rights to VIMOVO.
Spherix Announces Settlement Agreement and Continued Monetization of Patent Portfolio
Spherix Incorporated (SPEX) -- an intellectual property development company committed to the fostering and monetization of intellectual property, announced today that its wholly owned subsidiary, CompuFill LLC, has entered into a settlement and license agreement with a leading technology company.
This is the first settlement and license agreement for the CompuFill portfolio since Spherix acquired North South Holdings Inc. in September of 2013. Ongoing infringement enforcement continues as Spherix's model of patent monetization grows in both scope and size.
The CompuFill patents, each in the "on-line pharmacy automated refill system" sector, trace priority back to October 1997.